China Meheco Group Co

China Meheco Group Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co (600056.SS) as of Oct 18, 2026 is 230.92 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 120.79 % — a change of 91.17% (higher).

FCF Conversion

230.92 %

YoY

91.17%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co is 2025 230.92 % . FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co was 2024 120.79 % . It decreases by 91.17% higher compared to the previous year.

The China Meheco Group Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-16.94 CNY
Jan 1, 2019
-34.05 CNY
Jan 1, 2020
94.73 CNY
Jan 1, 2021
-21.28 CNY
Jan 1, 2022
192.62 CNY
Jan 1, 2023
47.38 CNY
Jan 1, 2024
120.79 CNY
Jan 1, 2025
230.92 CNY
The China Meheco Group Co FCF Conversion history
YEARFCF ConversionYoY
230.92 %+91.17%
120.79 %+154.96%
47.38 %-75.40%
192.62 %-1,004.95%
-21.28 %-122.47%
94.73 %-378.20%
-34.05 %+101.01%
-16.94 %-155.55%
30.50 %-65.94%
89.54 %-38.47%
145.51 %-10.84%
163.21 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

China Meheco Group Co Stock analysis

What does China Meheco Group Co do? China Meheco Group Co Ltd is a healthcare company based in Beijing, China, operating within the healthcare sector. The company has been publicly traded since May 15, 1997, with its stock listed under the ticker 600056.SS and ISIN CNE000000Q29. It employs 8,313 full-time staff. China Meheco Group engages in the wholesale distribution of medicines, drugs, and Chinese herbal medicine. The company's operations are structured into three main segments: Industrial Pharmaceutical, Commercial Pharmaceutical, and Trading. The Industrial Pharmaceutical segment focuses on the manufacturing and distribution of chemical preparations, chemical bulk drugs, biological products, Chinese patent medicine, and herbal decoction pieces. The Commercial Pharmaceutical segment handles the wholesale and distribution of pharmaceuticals and medical devices. The Trading segment is involved in international exporting and the introduction of medical resources. The company maintains a website at http://www.meheco.com for further information. China Meheco Group operates within the healthcare industry, contributing to the pharmaceutical supply chain in China and beyond through its diversified business segments. China Meheco Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about China Meheco Group Co stock

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co is 230.92 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of China Meheco Group Co changed from 120.79 % to 230.92 %, representing a 91.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) China Meheco Group Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s China Meheco Group Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — China Meheco Group Co

All Key Metrics — China Meheco Group Co